Newsfeeds Archive - Spark Newswire

2 minute read

What’s Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?

June 5, 3:17 PM

Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress 2024. Phase 2 tirzepatide trial shows promising results for MASH treatment. Further trials needed to confirm efficacy and safety.

AKRO

2 minute read

89bio Receives EMA PRIME Status For Pegozafermin In The Treatment Of Metabolic Dysfunction-Associated Steatohepatitis With Fibrosis And Compensated Cirrhosis

By Benzinga Newsdesk

March 27, 8:16 AM

–PRIME status is supported by positive data from the Phase 2b ENLIVEN trial of pegozafermin– –Phase 3 ENLIGHTEN-Fibrosis trial in non-cirrhotic MASH (fibrosis stage F2-F3) patients is enrolling and

ETNB

2 minute read

Liver Disease Player 89Bio Downgraded: Analyst Sees Short-Term Uncertainties In Fatty Liver Drug Development

By Vandana Singh

January 12, 3:41 PM

89Bio's journey in the clinical-stage biopharmaceutical space. RBC Capital Markets downgrades with insights on FGF21 drugs, pegozafermin, and 2024 uncertainties.

ETNB

1 minute read

Movers

12 Health Care Stocks Moving In Thursday’s After-Market Session

By Benzinga Insights

December 7, 5:31 PM

Gainers Exicure (NASDAQ:XCUR) stock rose 54.5% to $0.66 during Thursday’s after-market session. The market value of their outstanding…

ADIL

2 minute read

Sprinklr Reports Downbeat Earnings, Joins Chewy, GameStop And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session

By Avi Kapoor

December 7, 6:27 AM

U.S. stock futures traded mixed this morning, with the Dow Jones futures falling around 70 points on Thursday. Shares of Sprinklr, Inc. (NYSE: CXM) shares fell sharply in pre-market trading following weak earnings for the third quarter.

1 minute read

89bio Outlines Roadmap For Pivotal Studies For Lead Program In Fatty Liver Disease

By Vandana Singh

December 4, 12:38 PM

89bio Inc (NASDAQ: ETNB) announced a successful end-of-Phase 2 Meeting with the FDA supporting the advancement of pegozafermin into Phase 3 in

ETNB

2 minute read

Analyst Ratings

Analyst Ratings for 89bio

By Benzinga Insights

November 28, 9:00 AM

Over the past 3 months, 5 analysts have published their opinion on 89bio (NASDAQ:ETNB) stock. These analysts are…

ETNB

2 minute read

89bio’s Fatty Liver Candidate Shows Long-Term Improvement: Details

By Vandana Singh

November 27, 1:42 PM

89bio Inc (NASDAQ: ETNB) released topline data from the blinded extension phase of its Phase 2b ENLIVEN trial evaluating treatment with pegozafermin in patients with

ETNB

2 minute read

89bio Announces Additional Data From The ENLIVEN Phase 2b Trial Of Pegozafermin In Patients With Compensated Cirrhotic Nonalcoholic Steatohepatitis At AASLD The Liver Meeting 2023

By Benzinga Newsdesk

November 12, 6:15 PM

—Reductions in key non-invasive tests (NITs) of liver inflammation and fibrosis support previously demonstrated fibrosis improvements across compensated cirrhotic (F4) patients at week 24— —A responder analysis

ETNB